Table 3 Neuritic plaque pathology in Lewy pathology GBS subgroups of the two datasets.

From: A postmortem study suggests a revision of the dual-hit hypothesis of Parkinson’s disease

  

Global Lewy pathology Burden Score (GBS)

  

1–10

11–20

21–30

31+

 

CERAD

Vantaa dataset

Amygdala

0-A (n)

1

0

0

0

B-C (n)

9

11

9

9

Total (n)

10

11

9

9

Brainstem/PNS

0-A (n)

8

10

6

6

B-C (n)

8

6

11

18

Total (n)

16

16

17

24

All Vantaa cases

0-A (n)

9

10

6

6

B-C (n)

17

17

20

27

Total (n)

26

27

26

33

 

CERAD

Tokyo dataset

Amygdala

0-A (n)

11

7

7

13

B-C (n)

13

8

7

24

Total (n)

24

15

14

37

Brainstem/PNS

0-A (n)

25

10

8

0

B-C (n)

5

3

4

1

 

Total (n)

30

13

12

1

All Tokyo cases

0-A (n)

36

17

15

13

B-C (n)

18

11

11

25

 

Total (n)

54

28

26

38

  1. Global Burden Scores (GBS) signify the summed burden of Lewy pathology. The amygdala- and brainstem/PNS-predominant cases in both datasets are divided into GBS categories of global mild (1–10), moderate (11–20), severe (21–30), and very severe (31+) Lewy pathology. In each subgroup, the number of cases (n) with CERAD stage 0-A (none, mild) and B-C (moderate, severe) is listed. Note that the table does not contain the full samples from the two datasets, since 12 (10%) Vantaa cases and 32 (18%) Tokyo cases could not be unequivocally assigned to amygdala-predominant or brainstem/PNS-predominant categories, since they had equal amounts of pathology in the AMY + TOX and DMV + sympathetic structures used for categorization of cases.
Back to article page